Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Receives Average Recommendation of "Hold" from Brokerages

Key Points

• Mereo has a consensus "Hold" from eight analysts (1 sell, 4 hold, 3 buy) with an average 1‑year price target of $3.25.
• Multiple law firms have filed or solicited a securities‑class action (class period June 5, 2023–Dec 26, 2025) with an April 6, 2026 lead‑plaintiff deadline, creating litigation and potential settlement risk that could pressure the stock.
• Institutional investors own 62.83% of the company, and several funds recently increased positions (Woodline +53.2%, UBS AM +62.6%, Goldman Sachs added shares), signaling notable institutional inflows.

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO - Get Free Report) has earned a consensus recommendation of "Hold" from the eight analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $3.25.

A number of research firms recently issued reports on MREO. Robert W. Baird set a $1.00 price objective on Mereo BioPharma Group in a research note on Monday, December 29th. BTIG Research restated a "buy" rating and issued a $1.00 target price on shares of Mereo BioPharma Group in a research note on Friday, January 16th. Needham & Company LLC reduced their target price on Mereo BioPharma Group from $5.00 to $3.00 and set a "buy" rating for the company in a report on Tuesday, January 13th. Wall Street Zen cut Mereo BioPharma Group from a "hold" rating to a "sell" rating in a research report on Saturday, January 3rd. Finally, JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Mereo BioPharma Group in a report on Monday.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in MREO. Goldman Sachs Group Inc. raised its position in shares of Mereo BioPharma Group by 0.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,125,920 shares of the company's stock worth $4,783,000 after buying an additional 6,068 shares in the last quarter. Woodline Partners LP grew its position in Mereo BioPharma Group by 53.2% during the first quarter. Woodline Partners LP now owns 947,986 shares of the company's stock worth $2,133,000 after buying an additional 329,202 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Mereo BioPharma Group by 62.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,569,100 shares of the company's stock worth $3,530,000 after acquiring an additional 604,200 shares during the last quarter. XTX Topco Ltd bought a new position in Mereo BioPharma Group in the 2nd quarter worth about $188,000. Finally, Paloma Partners Management Co purchased a new stake in shares of Mereo BioPharma Group in the 2nd quarter valued at about $804,000. Institutional investors own 62.83% of the company's stock.

Key Headlines Impacting Mereo BioPharma Group

Here are the key news stories impacting Mereo BioPharma Group this week:

• Positive Sentiment: Reported decline in short interest earlier in March and a material short‑interest position (about 11.26M shares, ~7.5% of float) could reduce selling pressure and support the share price. (Data reported March 13–24; days‑to‑cover ~7.9 days.)
• Neutral Sentiment: JPMorgan Chase & Co. issued a Neutral rating on Mereo, a stance that may limit downside from analyst‑driven selling but does not constitute a buy catalyst. Mereo BioPharma Group NASDAQ: MREO Earns Neutral Rating from JPMorgan Chase & Co.
• Neutral Sentiment: Mereo is scheduled to release earnings soon, which can increase short‑term volatility but also provide fresh fundamental data that could change sentiment. Mereo BioPharma Group (MREO) to Release Earnings on Wednesday
• Negative Sentiment: Multiple nationally recognized law firms have filed or are soliciting investors in a securities‑class action against Mereo (class period: June 5, 2023–Dec 26, 2025) and are urging investors to seek lead‑plaintiff status before an April 6, 2026 deadline. The proliferation of filings/solicitations increases the likelihood of litigation costs, potential settlements or distraction for management—factors that typically pressure biotech equities. Representative notices include Rosen Law Firm and Robbins LLP. MREO FINAL DEADLINE: ROSEN... MREO Investor Alert - Robbins LLP

Mereo BioPharma Group Trading Up 4.1%

Mereo BioPharma Group stock opened at $0.35 on Thursday. The firm has a 50 day simple moving average of $0.43 and a 200 day simple moving average of $1.28. Mereo BioPharma Group has a 1-year low of $0.20 and a 1-year high of $3.05. The firm has a market capitalization of $55.66 million, a price-to-earnings ratio of -5.83 and a beta of 0.34.

Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) last posted its earnings results on Thursday, March 19th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). On average, equities research analysts forecast that Mereo BioPharma Group will post -0.03 EPS for the current year.

About Mereo BioPharma Group

Mereo BioPharma Group plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.

Mereo's pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.